LekoskopLekoskop
EN All changes
Medicine recalls and shortages › Recalls and defects › 27 Jan 2026
Medicines recall

Ocumont Eye Ointment 1% w/w

Issued on 27 Jan 2026 · source: MHRA — Medicines and Healthcare products Regulatory Agency
Affected batches: B0866 (30/11/2028)
Check the batch number on the pack. The medicine remains licensed; other batches are not affected.
Class 4 defect notification · DMRC-38025137 · PL: 31103/0018 · licence holder: Blumont Pharma Limited · active ingredient: chloramphenicol · licence PL: 31103/0018

What this means

The MHRA has issued a medicines recall or defect notification. Class 1: risk to life, immediate recall. Class 2: may cause mistreatment or harm, recall within 48 hours. Class 3: unlikely to cause harm, recall within 5 days. Class 4 (defect notification): no recall, caution in use. The medicine remains licensed; only the listed batches are affected. Do not stop treatment without speaking to your doctor or pharmacist.

Class 4 defect notification · DMRC-38025137

ProductLicenceActive ingredientGTIN
Ocumont Eye Ointment 1% w/wPL: 31103/0018chloramphenicol5060148680286

Batches (expiry): B0866 (30/11/2028)

Background: Blumont Pharma Limited is reporting to the MHRA regarding the absence of Braille on the outer carton of the above-mentioned batch of OCUMONT Eye Ointment 1% w/w (POM). It was identified that the Braille information was inadvertently omitted during the approval and release process. This issue is limited to a single batch (Lot B0866) that has been distributed. The quality of the ointment is not affected by this defect. All other batches distributed contain the Braille information on the outer carton. Advice for Healthcare Professionals:

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.